{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:14:52Z","timestamp":1790388892689,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2009,12,7]],"date-time":"2009-12-07T00:00:00Z","timestamp":1260144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,12,7]],"date-time":"2009-12-07T00:00:00Z","timestamp":1260144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1038\/bmt.2009.335","type":"journal-article","created":{"date-parts":[[2009,12,7]],"date-time":"2009-12-07T15:00:05Z","timestamp":1260198005000},"page":"1316-1324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan"],"prefix":"10.1038","volume":"45","author":[{"given":"C","family":"Dumontet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Plesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Bellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Barale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L M","family":"Pilarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Troncy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Tavtigian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Gemignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,7]]},"reference":[{"key":"BFbmt2009335_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BFbmt2009335_CR2","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495\u20132502.","journal-title":"N Engl J Med"},{"key":"BFbmt2009335_CR3","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1182\/blood-2003-02-0444","volume":"102","author":"RK Dasgupta","year":"2003","unstructured":"Dasgupta RK, Adamson PJ, Davies FE, Rollinson S, Roddam PL, Ashcroft AJ et al. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 2003; 102: 2345\u20132350.","journal-title":"Blood"},{"key":"BFbmt2009335_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3324\/haematol.10618","volume":"92","author":"C Schilthuizen","year":"2007","unstructured":"Schilthuizen C, Broyl A, van der Holt B, de Knegt Y, Lokhorst H, Sonneveld P . Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma. Haematologica 2007; 92: 277\u2013278.","journal-title":"Haematologica"},{"key":"BFbmt2009335_CR5","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/ijc.22411","volume":"120","author":"A Vangsted","year":"2007","unstructured":"Vangsted A, Gimsing P, Klausen TW, Nexo BA, Wallin H, Andersen P et al. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer 2007; 120: 1036\u20131045.","journal-title":"Int J Cancer"},{"key":"BFbmt2009335_CR6","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1182\/blood.V98.6.1922","volume":"98","author":"CM Galmarini","year":"2001","unstructured":"Galmarini CM, Graham K, Thomas X, Calvo F, Rousselot P, El Jafaari A et al. Expression of high Km 5\u2032-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood 2001; 98: 1922\u20131926.","journal-title":"Blood"},{"key":"BFbmt2009335_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/00008571-200208000-00006","volume":"12","author":"F Gemignani","year":"2002","unstructured":"Gemignani F, Landi S, Vivant F, Zienolddiny S, Brennan P, Canzian F . A catalogue of polymorphisms related to xenobiotic metabolism and cancer susceptibility. Pharmacogenetics 2002; 12: 459\u2013463.","journal-title":"Pharmacogenetics"},{"key":"BFbmt2009335_CR8","doi-asserted-by":"publisher","first-page":"816","DOI":"10.2144\/03354mt03","volume":"35","author":"S Landi","year":"2003","unstructured":"Landi S, Gemignani F, Gioia-Patricola L, Chabrier A, Canzian F . Evaluation of a microarray for genotyping polymorphisms related to xenobiotic metabolism and DNA repair. Biotechniques 2003; 35: 816\u2013820, 822, 824\u20137.","journal-title":"Biotechniques"},{"key":"BFbmt2009335_CR9","first-page":"16","volume":"16","author":"V Maggini","year":"2007","unstructured":"Maggini V, Buda G, Galimberti S, Conidi E, Giuliani N, Morabito F et al. Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms. Leuk Res 2007; 16: 16.","journal-title":"Leuk Res"},{"key":"BFbmt2009335_CR10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0093-7754(01)90036-3","volume":"28","author":"JR Berenson","year":"2001","unstructured":"Berenson JR, Ma HM, Vescio R . The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol 2001; 28: 626\u2013633.","journal-title":"Semin Oncol"},{"key":"BFbmt2009335_CR11","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1182\/blood.V94.8.2583.420a05_2583_2589","volume":"94","author":"H Avet-Loiseau","year":"1999","unstructured":"Avet-Loiseau H, Li JY, Morineau N, Facon T, Brigaudeau C, Harousseau JL et al. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood 1999; 94: 2583\u20132589.","journal-title":"Blood"},{"key":"BFbmt2009335_CR12","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1182\/blood.V97.6.1566","volume":"97","author":"T Facon","year":"2001","unstructured":"Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566\u20131571.","journal-title":"Blood"},{"key":"BFbmt2009335_CR13","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","volume":"109","author":"H Avet-Loiseau","year":"2007","unstructured":"Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489\u20133495.","journal-title":"Blood"},{"key":"BFbmt2009335_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","volume":"1","author":"KJ Rothman","year":"1990","unstructured":"Rothman KJ . No adjustments are needed for multiple comparisons. Epidemiology 1990; 1: 43\u201346.","journal-title":"Epidemiology"},{"key":"BFbmt2009335_CR15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1365-2141.2007.06605.x","volume":"137","author":"G Buda","year":"2007","unstructured":"Buda G, Maggini V, Galimberti S, Martino A, Giuliani N, Morabito F et al. MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol 2007; 137: 454\u2013456.","journal-title":"Br J Haematol"},{"key":"BFbmt2009335_CR16","doi-asserted-by":"crossref","unstructured":"Jamroziak K, Balcerczak E, Panczyk M, Piaskowski S, Janus A, Cebula B et al. Pharmacogenetic analysis of polymorphisms in pharmacological pathway of vincristine, doxorubicine and dexamethasone (VAD regimen) to predict response in patients with multiple myeloma. Am Soc Hematol 2005; Abstract 104.","DOI":"10.1182\/blood.V106.11.104.104"},{"key":"BFbmt2009335_CR17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1067\/mcp.2002.127739","volume":"72","author":"W Siegmund","year":"2002","unstructured":"Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002; 72: 572\u2013583.","journal-title":"Clin Pharmacol Ther"},{"key":"BFbmt2009335_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00008571-200302000-00005","volume":"13","author":"B Chowbay","year":"2003","unstructured":"Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ . Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13: 89\u201395.","journal-title":"Pharmacogenetics"},{"key":"BFbmt2009335_CR19","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1097\/01.ASN.0000073901.94759.36","volume":"14","author":"D Anglicheau","year":"2003","unstructured":"Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14: 1889\u20131896.","journal-title":"J Am Soc Nephrol"},{"key":"BFbmt2009335_CR20","first-page":"5340","volume":"58","author":"X Hu","year":"1998","unstructured":"Hu X, Xia H, Srivastava SK, Pal A, Awasthi YC, Zimniak P et al. Catalytic efficiencies of allelic variants of human glutathione S-transferase P1-1 toward carcinogenic anti-diol epoxides of benzo[c]phenanthrene and benzo[g]chrysene. Cancer Res 1998; 58: 5340\u20135343.","journal-title":"Cancer Res"},{"key":"BFbmt2009335_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0065-230X(08)60214-6","volume":"52","author":"K Sato","year":"1989","unstructured":"Sato K . Glutathione transferases as markers of preneoplasia and neoplasia. Adv Cancer Res 1989; 52: 205\u2013255.","journal-title":"Adv Cancer Res"},{"key":"BFbmt2009335_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0893-133X(00)00180-9","volume":"24","author":"SV Kyosseva","year":"2001","unstructured":"Kyosseva SV, Owens SM, Elbein AD, Karson CN . Differential and region-specific activation of mitogen-activated protein kinases following chronic administration of phencyclidine in rat brain. Neuropsychopharmacology 2001; 24: 267\u2013277.","journal-title":"Neuropsychopharmacology"},{"key":"BFbmt2009335_CR23","first-page":"4053","volume":"60","author":"Z Yin","year":"2000","unstructured":"Yin Z, Ivanov VN, Habelhah H, Tew K, Ronai Z . Glutathione S-transferase p elicits protection against H2O2-induced cell death via coordinated regulation of stress kinases. Cancer Res 2000; 60: 4053\u20134057.","journal-title":"Cancer Res"},{"key":"BFbmt2009335_CR24","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1182\/blood-2004-11-4286","volume":"106","author":"Q Chen","year":"2005","unstructured":"Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS . The FA\/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 2005; 106: 698\u2013705.","journal-title":"Blood"},{"key":"BFbmt2009335_CR25","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1158\/0008-5472.CAN-06-0877","volume":"67","author":"Z Chen","year":"2007","unstructured":"Chen Z, Yang J, Wang G, Song B, Li J, Xu Z . Attenuated expression of xeroderma pigmentosum group C is associated with critical events in human bladder cancer carcinogenesis and progression. Cancer Res 2007; 67: 4578\u20134585.","journal-title":"Cancer Res"},{"key":"BFbmt2009335_CR26","first-page":"6","volume":"6","author":"Y Zhu","year":"2007","unstructured":"Zhu Y, Yang H, Chen Q, Lin J, Grossman HB, Dinney CP et al. Modulation of DNA damage\/DNA repair capacity by XPC polymorphisms. DNA Repair 2007; 6: 6.","journal-title":"DNA Repair"},{"key":"BFbmt2009335_CR27","doi-asserted-by":"crossref","unstructured":"Van Ness BG, Crowley JC, Ramos C, Grindle S, Rasmussen E, Hoering A et al. SNP genotypes show association with common toxicities during both VAD induction and high dose melphalan with autologous transplant support in Intergroup Trial S9321 for Myeloma: From the Bank on a Cure. Am Soc Hematol 2005; Abstract 3488.","DOI":"10.1182\/blood.V106.11.3488.3488"},{"key":"BFbmt2009335_CR28","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Schilthuizen C, Lokhorst H, Vellenga E, Raymakers R, de Knegt Y et al. Influence of genetic single nucleotide polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and treatment related toxicity in patients with multiple myeloma treated in the HOVON 24 Trial. Am Soc Hematol 2005; 111; Abstract 505.","DOI":"10.1182\/blood.V106.11.505.505"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2009335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2009335","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2009335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T12:30:22Z","timestamp":1648038622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2009335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,7]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["BFbmt2009335"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2009.335","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,7]]},"assertion":[{"value":"20 April 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}